CNBC Stock Blog
- 3 Safe Investments That Let You ‘Sleep Better:’ Strategist
- Beware of 'Trampling Effect' When Market Tops: Manager
- Gold Heading to $1150: Art Hogan
- More Upside if S&P Passes This Number: Market Pro
- Playing Activision and Other Video Game Stocks: Analyst
- Expect 'At Least' Another 10-15% Upside: Fund Manager
- Why are Options Bullish on This Smartphone Maker?
- Why are Traders Bullish on This Food Company?
- Profiting From Natural Gas: Strategists
- 3 Hot Mid-Cap Stock Picks: Portfolio Manager
MOST SHARED
- Herbalife Vs. Hedge Funds
- Apple Surpasses Nokia as Top Cellphone Maker by Profits
- JPMorgan Chase to Hire 1,200 Mortgage Officers
- Gold Heading to $1150: Art Hogan
- Parsing Treasury's Loan Modification Report
- Adobe Cuts 680 Jobs, to Take Charge
- Cramer Jeers J&J, Applauds Abbott
- Toll Brothers: More Contracts Signed, but Sales Down
- Bear Stearn Fund Managers Not Guilty on All Counts
- Beware of 'Trampling Effect' When Market Tops: Manager
- Gold Heading to $1150: Art Hogan
- Starbucks Brews Up Growth
- Farr: An Extended Period—No Fat Lady in Sight
- More Upside if S&P Passes This Number: Market Pro
- Murdoch Lashes Out At Google
- Fighting The Flu Vaccine Critics
- Nov. 10: Unusual Volume Leaders
- Shadow Inventory Dwarfs Loan Mods
- Retail Earnings in Focus Ahead of Shopping Season
- Apple Surpasses Nokia as Top Handset Maker by Profit
- In This Relay-Race Market, Who Gets Baton Next?
- Workers Staying Put at Their Jobs as Jobless Surges
- Three Things the US Can Do To Stop the Dollar's Decline
- Toll Brothers: More Contracts Signed, but Sales Down
- Ponzi Proceeds: Bidding on Madoff's Toys
- Bear Stearn Fund Managers Not Guilty on All Counts
- Commodity ETFs: Returns May Not Match Expectations
RSS FEED
Text Size 
CNBC News Associate
Dr. Mark Monane, senior biotech analyst at Needham & Co., named some biotech stocks that look attractive.
Recommendations:
Allos Therapeutics [ALTH
Loading...
()
]—The company has a positive last trial for treating T-cell lymphoma, bladder cancer and lung cancer. “People may be treated in the real world by the end of this year,” Monane told CNBC.
Medarex [MEDX
Loading...
()
]—The company is in its late stage programs in testing melanoma, a tough-to-treat cancer. They also have solid partnerships with Bristol-Myers [BMY
Loading...
()
], Merck [MRK
Loading...
()
] and Johnson & Johnson [JNJ
Loading...
()
].
Cubist Pharmaceuticals [CBST
Loading...
()
]
Vertex Pharmaceuticals [VRTX
Loading...
()
]—They are in their last phase in developing a treatment for Hepatitis C.
Disclosure:
No immediate information was available for Monane or his firm.
______________________________
______________________________
Data is a real-time snapshot *Data is delayed at least 15 minutes